Translating research findings into clinical practice: a systematic and critical review of neuroimaging-based clinical tools for brain disorders - Cortechs.ai

Translating research findings into clinical practice: a systematic and critical review of neuroimaging-based clinical tools for brain disorders

November 18, 2023
< 1 mins

Category: Published research
Product: NeuroQuant

This systematic review describes and compares the technical characteristics of the available tools, with the aim to assess their translational potential into real-world clinical settings. The results reveal that a total of eight tools. All of these were specifically developed for neurological disorders, and as such are not suitable for application to psychiatric disorders. 2020.

[button]Download[/button]

Topic: Published research

More Resources

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

Blogs

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

Blogs

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

Cortechs.ai news, Industry news, Product updates

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

Cortechs.ai news, Industry news, Product updates

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

Product updates

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

Blogs, Product updates

Empowering precision

and clarity in patient care

727 Madison Ave, Suite 29, Covington, Kentucky 41011

Headquarters:

5060 Shoreham Place,
Ste 240, San Diego, CA 92122